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1 Introduction
The problem was posed by Seyed Moghadas, from the National Research Council Insti-
tute for Biodiagnostics in Winnipeg, Manitoba. It concerns the optimization of the rate of
treatment with antivirals during a pandemic of influenza, to achieve the following objectives:
1. Minimize the total number of deaths due to influenza.
2. Minimize the total number of infections with influenza.
3. Reduce the spread of resistance to antivirals.
It is understood that not all the objectives above might be satisfied at the same time, and
the purpose of the work is to consider the outcome in the different scenarios.
Antivirals generally target specific proteins on or in the virus and deactivate them,
thereby suppressing the ability of the viruses to reproduce or infect target cells. Typically,
they result in a reduction of the duration of symptoms and, in the case of influenza, pre-
vent or attenuate some of the complications resulting from infection with the virus. Some
antivirals can also be used in a prophylactic capacity, and may prevent infections arising in
uninfected individuals.
The use of antivirals can therefore greatly alleviate the impact of an epidemic, by
reducing the period of infectivity and by reducing the mortality associated to the epidemic.
However, the indiscriminate use of antivirals in recent years has had an adverse effect. A
well known antiviral for influenza, oseltamivir (Tamiflu), was first shown to induce resistance
in some of the circulating viral strains [7]. Such resistance has also been observed in other
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types of antivirals, such as adamantane [8]. In the October-December 2005 period, 193 of
209 (92.3%) isolates of H3N2 human influenza virus in the United States tested positive for
resistance to a certain type of antivirals (M2-inhibitors) [4].
Resistance has several correlated effects. Firstly, because it does not stop the viral
progression in the host, it does not avert the adverse effects of influenza, and hence does
not contribute to a reduction of mortality. Secondly, as it does not reduce the period of
infectivity, it does not reduce the probability of new infections and thus has no effect on the
control of the disease. Thirdly, because identifying the strain an individual bears requires
lengthy and costly procedures, antivirals may be provided to individuals who are infected
with a resistant strain, which amounts to a waste of resources since antivirals are useless
on such individuals [2].
In these circumstances, while it is desirable to use antivirals, their use must also be
conducted in a reasonable fashion, so as to avoid as much as possible the emergence of
resistant strains[5, 6]. The aim of the present project is to see if optimal control theory can
contribute to a better formulation of the treatment intensity, in order to bring the epidemic
under control while avoiding wide-spread resistance in the population.
2 The model
We assume that the model takes the form shown in Figure 1. Starting as susceptible (S),
individuals can then become infected with either the sensitive strain or with the resistant
strain. Infection by the sensitive strain occurs when a susceptible has an infecting contact
with either an untreated (IU ) or a treated (IT ) individual bearing the sensitive strain.
Infection with the resistant strain occurs through contact with either an untreated (IR) or
a treated (IW ) individual bearer of the resistant strain. In both cases, it is assumed that
upon infection, a susceptible enters the untreated (sensitive or resistant) class.
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Figure 1 Flow chart illustrating the structure of the model.
An individual entering the untreated sensitive class IU has several possibilities. He can
become treated, at the per capita rate u, in which case he progresses to the IT class. He
can recover, at the per capita rate γU , or he can die, at the per capita rate dU . A treated
individual with the sensitive strain can also either recover or die at the per capita rates γT
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and dT , respectively. But the treatment can also cause the apparition of resistance. This
happens at the per capita rate r. Evolving resistance means that the individual progresses
to the class IW of treated individuals who have the resistant strain.
The other route to the IW class is through direct infection by a bearer of the resistant
strain. Upon infection, a susceptible infected by the resistant strain progresses to the IR
class, where, similarly to what happens with the sensitive strain, he can be treated, recover
or die at the per capita rates u, γR and dR, respectively. Treatment of individuals in the IW
class constitutes a waste of drugs, since they have no effect on the resistant strain. Hence
individuals in the IW class have the same recovery and death rates as those in the IR class.
The classes R and D are used to count individuals who have recovered or died from the
disease, respectively. Lastly, the P class represents the number of new courses of treatment
that are available at time t, that is, how many new infected individuals can be treated.
We consider the system
S′ = −(βUIU + βT IT + βR(IR + IW ))S (2.1a)
I ′U = (βUIU + βT IT )S − (u+ γU + dU )IU (2.1b)
I ′T = uIU − (dT + γT + r)IT (2.1c)
I ′R = βR(IR + IW )S − (u+ γR + dR)IR (2.1d)
I ′W = uIR + rIT − (γR + dR)IW (2.1e)
R′ = γUIU + γT IT + γR(IR + IW ) (2.1f)
D′ = dUIU + dT IT + dR(IR + IW ) (2.1g)
P ′ = −u(IU + IR), (2.1h)
with initial conditions S(0) = S0 > 0, IU = I0 ≥ 0, IT = IR = IW = R = D = 0 and
P (0) = ∆ ≥ 0. The initial condition ∆ represents the total number of courses of treatment
that can be initiated at time t = 0.
3 Optimal control
We will make use of the Pontryagin maximum principle. We recall here the general
principles of this approach (see, e.g., [1, 3]). Given an initial value problem
x′ = f(t, x(t), u(t)), x(t0) = x0, (3.1)
one defines a cost functional
J =
∫ T
t0
F (t, x(t), u)dt (3.2)
to be minimized. The function u(t) is the control. Note that here we consider finite-time
control, in the sense that the solution to (3.1) is considered only on the interval [0, T ]. The
form (3.2) is not the most general, but corresponds to what will be used later. Such a
functional defines a Lagrange problem. Other forms are those where the cost function only
depends on the trajectory at the terminal moment T (Mayer problem) or a combination of
Lagrange and Mayer problems (Boltz problem).
Our aim will be to minimize J (using admissible values of u), not to obtain a prescribed
end state of the system. Our problem is thus one with variable end point and fixed time.
The following result holds [1], which we state in its classical form involving a maximum.
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Theorem 3.1 (Pontryagin maximum principle) Let u0(t) be the optimal control in the
problem
x′ = f(t, x(t), u(t)), x ∈ Rn, u ∈ Rm, t0 ≤ t ≤ T, x(t0) = x0
J(u) = φ(x(T ))→ inf,
u(t) ∈ U
and x0(t) be the corresponding optimal trajectory. Then u0(t) satisfies the maximum con-
dition
max
u∈U
H(t, x0(t), u, ψ(t)) = H(t, x0(t), u0(t), ψ(t)). (3.3)
The Hamiltonian is determined by the expression
H(t, x(t), u(t), ψ(t)) = ψ′(t)f(t, x(t), u(t)),
and the adjoint variables ψ(t) are solutions of the problem
ψ′(t) = −Hx(t, x0(t), u0(t), ψ(t)) ψ(T ) = −φx(x0(T )).
We will see in the following sections how this result is applied to our system.
3.1 Cost functional used. We use
min
0≤u(t)≤u¯
∫ T
0
L ds, (3.4)
where
L := D′(s) + εu(s)2(IU (s) + IR(s)) (3.5)
under the constraint that
P (T ) ≥ 0. (3.6)
The functional (3.5) accounts for the number of deaths due to the disease as well as a cost of
treatment. The quantity
∫ T
0 D
′(s)ds gives the total number of deaths over the time interval
[0, T ]. The cost of treatment is here assumed to be a quadratic function of the treatment
rate u. Using this hypothesis enables to avoid a bang-bang control.
The value u¯ is the maximal possible rate of treatment. It is a function of infrastructure.
For example, the treatment rate might be limited by the number of healthcare workers able
to administer it, or by the number of hospital beds available.
3.2 Hamiltonian and adjoint system. We form the Hamiltonian
H := λ1S′ + λ2I ′U + λ3I ′T + λ4I ′R + λ5I ′W + λ6R′ + λ7D′ + λ8P ′ + L. (3.7)
Solving ∂H/∂u = 0, we find that
u∗ =
(λ2 − λ3)IU + (λ4 − λ5)IR
2ε(IU + IR)
. (3.8)
It is here that the assumption of quadratic dependence on the treatment rate u made in
(3.5) plays a role: if L depends linearly on u, then ∂H/∂u = 0 cannot be solved for u and
we have to assume that u∗ = 0 or u = u∗, that is, bang bang control.
To find the adjoint variables, we use λ′i = −∂H/∂xi, where xi ∈ {S, IU , IT , IR, IW , R,D, P}.
We start by noticing that
∂H
∂R
=
∂H
∂D
=
∂H
∂P
= 0.
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Since the terminal conditions are λi(T ) = 0, it follows from uniqueness of solutions that
λ6 ≡ λ7 ≡ λ8 ≡ 0. Using this fact, we find the dynamics of the other adjoint variables to
be given by
λ′1 = (βUIU + βT IT )(λ1 − λ2) + βR(IR + IW )(λ1 − λ4) (3.9a)
λ′2 = βUS(λ1 − λ2) + (u∗ + γU + dU )λ2 − u∗λ3 − dU − εu∗2 (3.9b)
λ′3 = βTS(λ1 − λ2) + (dT + γT + r)λ3 − rλ5 − dT (3.9c)
λ′4 = βRS(λ1 − λ4) + (u∗ + γR + dR)λ4 − u∗λ5 − dR − εu∗2 (3.9d)
λ′5 = βRS(λ1 − λ4) + (γR + dR)λ5 − dR, (3.9e)
with u∗ given by (3.8). System (3.9) is considered with terminal conditions λi(T ) = 0.
3.3 Numerical solution of the problem. To explain the method used to construct
numerical solutions to the optimal control problem, we let x ∈ R8 represent the state vari-
ables {S, IU , IT , IR, IW , R,D, P} and Λ ∈ R5 represent the adjoint variables {λ1, λ2, λ3, λ4, λ5}.
Systems (2.1) and (3.9) can then be written as
x′ = f(x,Λ) (3.10a)
Λ′ = g(x,Λ) (3.10b)
under the initial and terminal conditions
x(0) = ξ0
Λ(T ) = 0.
We construct a convergent sequence of approximations (xk(t),Λk(t)) to the solution to this
boundary value problem as follows.
1. Start with an initial guess solution Λ0(t) for t ∈ [0, T ]. For example, Λ0(t) ≡ 0 for
t ∈ [0, T ].
2. Integrate (3.10a) from t = 0 to t = T , using Λ0(t) as a nonautonomous component
and the initial condition x(0) = ξ0. This gives x0(t).
3. Integrate (3.10b) backward in time from t = T to t = 0, using the solution xk(t) as a
nonautonomous component and the initial condition Λ(T ) = 0. This gives Λk+1(t).
4. Integrate (3.10a) from t = 0 to t = T , using the value of Λk+1(t) found in step 3 as a
nonautonomous component and the initial condition x(0) = ξ0. This gives xk+1(t).
5. Repeat steps 3 and 4 until convergence.
3.4 Practical implementation of the algorithm. Some caution is required when
using the algorithm presented above. Because of the nature of (3.8), the problem can be
stiff when IU and IR become close to zero. As a consequence, it was necessary to use a stiff
routine such as ode15s. Because adaptive step size routines produce by default values at
time points that vary from iteration to iteration, we use the format
ode15s(@rhs_fct,[t0:tstep:tf],IC)
that allows to specify the time points at which output is to be produced. The main loop
explained in the previous section can be carried out, in Matlab, using the following simple
loop:
[t,x]=ode15s(@rhs_state_eq,t_positive,IC_state,[],p);
p.x=[x,p.x(1:end,9:13)];
[t,x]=ode15s(@rhs_adjoint_eq,t_negative,IC_adjoint,[],p);
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p.x=[p.x(1:end,1:8),flipud(x)];
Using this method and storing the result in the structure p allows to reduce the number of
operations and the size in memory of the variables.
4 Numerical results
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Figure 2 Situation with no run-out both in the optimally controlled and the constantly
controlled cases, for a total population of 1000 individuals. (a) Numbers of infectious
individuals in the various infectious classes, as well as cumulative number of deaths, optimal
control case. (b) Numbers of infectious individuals in the various infectious classes, as well
as cumulative number of deaths, constant control case. (c) Number of new infectious that
be treated (P ) in the optimal control and constant control (no control) cases, and scaled
treatment rate (u) in the optimal control case.
In Figures 2 to 5, we display three items:
(a) The numbers of individuals in the different infected classes (IU , IT , IR and IW ) as
well as the cumulative number of deaths, as a function of time, in the case where the
optimal control policy is applied.
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(b) The same quantities, but in the case with no optimal control, that is, with a constant
treatment rate applied as long as there remains some courses of treatment.
(c) The number of courses of treatment available as a function of time, in the case of
optimal control (control) and constant treatment (no control). In the case with
optimal control, the scaled treatment rate used as a function of time is also shown.
The figures are ordered by decreasing number of initially available courses of treatment,
all other parameters and initial conditions being considered equal throughout simulations.
In Figure 2, there are initially resources for the treatment of 500 new infectives. This
number is sufficient even when a constant treatment rate is applied. The effect of (3.5) is
clearly visible. Figure 2(a)
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Figure 3 Situation with no run-out in the optimally controlled case and run-out in the
constantly controlled case, for a total population of 1000 individuals. (a) Numbers of
infectious individuals in the various infectious classes, as well as cumulative number of
deaths, optimal control case. (b) Numbers of infectious individuals in the various infectious
classes, as well as cumulative number of deaths, constant control case. (c) Number of new
infectious that be treated (P ) in the optimal control and constant control (no control)
cases, and scaled treatment rate (u) in the optimal control case.
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In Figure 3, there are initially enough courses of treatment when optimal control is
used, but not enough in the case of constant treatment, where run-out occurs. Note that,
interestingly, there is a second wave of resistant infection taking place after run-out, in the
case where constant treatment is used.
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Figure 4 Situation with no run-out in the optimally controlled case and run-out in the
constantly controlled case, for a total population of 1000 individuals. (a) Numbers of
infectious individuals in the various infectious classes, as well as cumulative number of
deaths, optimal control case. (b) Numbers of infectious individuals in the various infectious
classes, as well as cumulative number of deaths, constant control case. (c) Number of new
infectious that be treated (P ) in the optimal control and constant control (no control)
cases, and scaled treatment rate (u) in the optimal control case.
Figure 4 is very similar to Figure 3, with the difference that run-out occurs sooner in
the uncontrolled case, so that the resistant infection is increasing at that time.
Note that in Figures 3 and 4, the optimal control policy consists in treating at the
maximum rate (the same as in the uncontrolled case) until some time, then rapidly shutting
off treatment, which is a sort of continuous version of bang bang control.
Optimal Treatment Rate During an Influenza Pandemic 9
0 20 40 60 80 100 120 140 160 180 200
0
20
40
60
80
100
120
Time (days)
 
 
IU
IT
IR
IW
D
(a)
0 20 40 60 80 100 120 140 160 180 200
0
20
40
60
80
100
120
Time (days)
 
 
IU
IT
IR
IW
D
(b)
0 20 40 60 80 100 120 140 160 180 200
0
10
20
30
40
50
60
70
80
90
100
Time (days)
 
 
P (control)
u (scaled)
P (no control)
(c)
Figure 5 Situation with run-out both in the optimally controlled and the constantly
controlled cases, for a total population of 1000 individuals. (a) Numbers of infectious
individuals in the various infectious classes, as well as cumulative number of deaths, optimal
control case. (b) Numbers of infectious individuals in the various infectious classes, as well
as cumulative number of deaths, constant control case. (c) Number of new infectious that
be treated (P ) in the optimal control and constant control (no control) cases, and scaled
treatment rate (u) in the optimal control case.
5 Conclusion
Using a treatment rate obtained using optimal control theory seems an efficient way to
mitigate the epidemic while avoiding the spread of resistance. The most striking feature
of the optimal control approach is in its capacity to reduce the waste of antivirals, as seen
when comparing, in Figures 2 to 5, the cases with and without optimal treatment.
Further work will be needed to explore more in detail the model and its conclusions. In
particular, a comparison of optimization criteria (cost functionals) should be undertaken,
to assure that the strategy deduced using optimal control does not depend too much on the
nature of the functional.
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